Showing results (1-10 of 379) with videos related to
Sort By:
Pageof 38
F1000Research|December 14, 2018
New hypoglycemic agents and the kidney: what do the major trials tell us?Brendan Smyth, Vlado PerkovicDiabetes & Vascular Disease Research|March 3, 2012
Effects of SGLT2 inhibitors on cardiovascular outcomesCeline Foote, Vlado Perkovic, Bruce NealCurrent Opinion in Nephrology and Hypertension|September 28, 2023
Combination therapy with kidney protective therapies: optimizing the benefits?Sradha Kotwal, Evan Perkovic, Vlado PerkovicContributions to Nephrology|June 11, 2011
Intensive glycemic control and renal outcomeMin Jun, Vlado Perkovic, Alan CassNephrology (Carlton, Vic.)|October 4, 2006
Diuretics: a modern day treatment option?Martin Gallagher, Vlado Perkovic, John ChalmersExpert Review of Clinical Pharmacology|August 1, 2022
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuriaNasir Shah, Vlado Perkovic, Sradha KotwalCurrent Opinion in Nephrology and Hypertension|October 9, 2014
Optimal targets for blood pressure control in chronic kidney disease: the debate continuesJohn Knight, Muh Geot Wong, Vlado PerkovicJournal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 29, 2006
ADVANCE: breaking new ground in type 2 diabetesJohn Chalmers, Vlado Perkovic, Rohina Joshi, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 1, 2020
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?Brendon L Neuen, Meg J Jardine, Vlado PerkovicCurrent Medical Research and Opinion|October 24, 2015
Renal effects of canagliflozin in type 2 diabetes mellitusVlado Perkovic, Meg Jardine, Ujjwala Vijapurkar, et al.Pageof 38